BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 8757979)

  • 1. Varying temperature-dependence of post-attachment neutralization of human immunodeficiency virus type 1 by monoclonal antibodies to gp 120: identification of a very early fusion-independent event as a neutralization target.
    Armstrong SJ; Dimmock NJ
    J Gen Virol; 1996 Jul; 77 ( Pt 7)():1397-402. PubMed ID: 8757979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
    Armstrong SJ; McInerney TL; McLain L; Wahren B; Hinkula J; Levi M; Dimmock NJ
    J Gen Virol; 1996 Dec; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies.
    McLain L; Dimmock NJ
    J Gen Virol; 1994 Jun; 75 ( Pt 6)():1457-60. PubMed ID: 8207410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
    Vijh-Warrier S; Pinter A; Honnen WJ; Tilley SA
    J Virol; 1996 Jul; 70(7):4466-73. PubMed ID: 8676471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1.
    Hioe CE; Hildreth JE; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 1999 Apr; 15(6):523-31. PubMed ID: 10221529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
    Back NK; Smit L; De Jong JJ; Keulen W; Schutten M; Goudsmit J; Tersmette M
    Virology; 1994 Mar; 199(2):431-8. PubMed ID: 8122371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1.
    Schønning K; Jansson B; Olofsson S; Hansen JE
    J Gen Virol; 1996 Apr; 77 ( Pt 4)():753-8. PubMed ID: 8627264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postattachment neutralization of a primary strain of HIV type 1 in peripheral blood mononuclear cells is mediated by CD4-specific antibodies but not by a glycoprotein 120-specific antibody that gives potent standard neutralization.
    McInerney TL; Dimmock NJ
    AIDS Res Hum Retroviruses; 2001 Nov; 17(17):1645-54. PubMed ID: 11779352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
    Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
    J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties and mechanism of action of a 17 amino acid, V3 loop-specific microantibody that binds to and neutralizes human immunodeficiency virus type 1 virions.
    Jackson NA; Levi M; Wahren B; Dimmock NJ
    J Gen Virol; 1999 Jan; 80 ( Pt 1)():225-236. PubMed ID: 9934706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization.
    Zhang YJ; Fredriksson R; McKeating JA; Fenyö EM
    Virology; 1997 Nov; 238(2):254-64. PubMed ID: 9400598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion.
    Heap CJ; Reading SA; Dimmock NJ
    J Gen Virol; 2005 May; 86(Pt 5):1499-1507. PubMed ID: 15831963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of primary human immunodeficiency virus type 1 envelope glycoprotein-mediated entry by human antibodies.
    Schutten M; Andeweg AC; Rimmelzwaan GF; Osterhaus AD
    J Gen Virol; 1997 May; 78 ( Pt 5)():999-1006. PubMed ID: 9152416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization titres of HIV-1-specific monoclonal antibodies vary according to the batch of primary human peripheral blood lymphocytes, but do not vary coordinately.
    McLain L; Armstrong SJ; Dimmock NJ
    J Virol Methods; 1997 Aug; 67(1):69-76. PubMed ID: 9274819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-Neutralization Activity of Single-Chain Variable Fragment (scFv) Derived from Anti-V3 Monoclonal Antibodies Mediated by Post-Attachment Binding.
    Maruta Y; Kuwata T; Tanaka K; Alam M; Valdez KP; Egami Y; Suwa Y; Morioka H; Matsushita S
    Jpn J Infect Dis; 2016 Sep; 69(5):395-404. PubMed ID: 26902223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.